Health Care • Other Pharmaceuticals
$12.93 ▼ -0.45
(-3.36%)
MKT CAP: $1.36B • VOL: 1.65M
52W L $8 52W H $20
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$11
MEDIAN
$14
MEAN
$15
HIGH
$18
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE HLF TAPE
HLF // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $15.65 | $14.87 | 2025-02-14 | $11.77 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $16.29 | $15.26 | 2025-02-06 | $12.15 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $14.74 | $14.22 | 2025-01-29 | $12.41 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $13.19 | — | 2025-01-17 | $12.67 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $11.38 | $12.28 | 2025-01-09 | $11.51 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $15.39 | $13.45 | 2024-12-18 | $11.25 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $12.54 | $13.06 | 2024-12-04 | $12.02 | -4.3% | 48% | C |